Fumagillin regulates stemness and malignancies in cancer stem-like cells derived from liver cancer via targeting to MetAP-2
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0289024 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift PLOS ONE, 2023. Verfasst von Ke Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Second People's Hospital of Yibin, Sichuan, China. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Liver Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The General Program (Key Program, Major Research Plan) of National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Cancer relapse is associated with the presence of cancer stem-like cells (CSCs), which lead to multidirectional differentiation and unrestricted proliferative replication. Fumagillin, a myocotoxin produced by the saprophytic filamentous fungus Aspergillus fumigatus, has been reported to affect malignant characteristics in hepatocellular cancer cells. However, its exact role in CSCs is still unknown.
Methods
CSCs were enriched by culturing cancer cells in serum-free medium. The effects of fumagillin on malignant cell characteristics and mitochondrial function were measured. The regulatory role of fumagillin on methionine aminopeptidase-2 (MetAP-2) was assessed.
Results
When it was supplemented in medium, fumagillin treatment inhibited sphere formation and the maintenance of stemness of CSCs without disturbing cell growth. Fumagillin also decreased stemness-related markers and the aldehyde dehydrogenase 1 (ALDH1)-positive proportion, which demonstrated that fumagillin decreases stemness in CSCs. It was also found to inhibit malignant traits in CSCs, including cell proliferation, invasion, and tumor formation, and sensitize CSCs to chemoagents, including sorafenib and doxorubicin, by promoting chemoagent-induced apoptosis. Moreover, fumagillin treatment was found to disturb mitochondrial membrane homeostasis, ATP synthesis and mitochondrial transcriptional activity. In addition, we found that fumagillin decreased MetAP-2 protein levels and exerted anti-CSC effects potentially by regulating MetAP-2. We also found that fumagillin treatment activated p53 and its transcriptional activity and thus caused cell cycle blockade. Moreover, fumagillin treatment significantly decreased tumor formation in nude mice.
Conclusion
This work offers evidence for fumagillin as a specific inhibitor of liver cancer CSCs and proposes a novel strategy for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Second People's Hospital of Yibin, Sichuan, China.
- TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan, China.
ORCID-Profile: Ziyi Zhao
Förderung
- The General Program (Key Program, Major Research Plan) of National Natural Science Foundation of China
Zitieren
APA
Zhang, K., Hu, J., & Zhao, Z. (2023). Fumagillin regulates stemness and malignancies in cancer stem-like cells derived from liver cancer via targeting to MetAP-2. PLOS ONE. https://doi.org/10.1371/journal.pone.0289024
Vancouver
Zhang K, Hu J, Zhao Z. Fumagillin regulates stemness and malignancies in cancer stem-like cells derived from liver cancer via targeting to MetAP-2. PLOS ONE. 2023. doi:10.1371/journal.pone.0289024
BibTeX
@article{Zhang2023,
author = {Zhang, Ke and Hu, Jian and Zhao, Ziyi},
title = {Fumagillin regulates stemness and malignancies in cancer stem-like cells derived from liver cancer via targeting to MetAP-2},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0289024}
}
EUVIMED